Nyrada Inc
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
180 George Street, Sydney Place
Level 22/23, Salesforce Tower
SydneyNSW2000
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
stocks
ASX energy giant undervalued despite commissioning challenges
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,199.70 | 30.70 | 0.33% |
| CAC 40 | 8,405.50 | 53.28 | -0.63% |
| DAX 40 | 25,448.08 | 15.93 | -0.06% |
| Dow JONES (US) | 52,747.32 | 537.24 | 1.03% |
| FTSE 100 | 10,892.72 | 21.70 | 0.20% |
| HKSE | 25,807.92 | 497.07 | 1.96% |
| NASDAQ | 24,876.91 | 55.17 | -0.22% |
| Nikkei 225 | 61,434.19 | 930.73 | -1.49% |
| NZX 50 Index | 13,976.67 | 114.74 | 0.83% |
| S&P 500 | 7,428.78 | 15.60 | 0.21% |
| S&P/ASX 200 | 9,038.60 | 35.10 | 0.39% |
| SSE Composite Index | 3,828.47 | 15.15 | 0.40% |